Solid Tumor Targeting CAR-T Development Service by Inhibiting IDO & ARG1

Are you currently facing low response rates in solid tumors, severe T cell exhaustion, or a highly immunosuppressive Tumor Microenvironment (TME)? Creative Biolabs' Solid Tumor Targeting CAR-T Development Service by Inhibiting IDO & ARG1 helps you deliver highly persistent and effective CAR-T cell therapies for solid tumors through dual metabolic checkpoint blockade and TME reprogramming. We provide solutions that overcome the primary metabolic barriers to T cell function and survival.

Introduction

IDO and ARG1 function as critical metabolic immune checkpoints that deplete essential amino acids, tryptophan and arginine, within the tumor microenvironment. This depletion significantly impairs effector T cell function and proliferation, while promoting the expansion of immunosuppressive populations such as regulatory T cells, thereby undermining antitumor immune responses. Inhibition of IDO and ARG1 can effectively reverse this local immunosuppression, restore the metabolic fitness and cytotoxic capacity of CAR-T cells, and enhance their tumor infiltration and sustained antitumor activity. Consequently, combining IDO/ARG1 inhibitors with CAR-T therapy not only improves T cell survival and functional persistence in immunosuppressive milieus but also holds promise for overcoming current therapeutic limitations, potentially elevating clinical response rates and long-term efficacy in solid tumor treatments.

Fig.1 IDO expression across immune compartments in cancer.¹

Solid Tumor Targeting CAR-T Development Service by Inhibiting IDO & ARG1 at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service by Inhibiting IDO & ARG1 provides a comprehensive development platform for creating solid tumor-resistant CAR-T cells through dual metabolic checkpoint blockade. We employ genetic engineering and pharmacological strategies to simultaneously target the IDO1/kynurenine and ARG1/L-arginine pathways, enhancing the persistence and effector function of CAR-T products.

What We Can Offer

We offer a comprehensive portfolio of IDO/ARG1-targeting solutions, from small-molecule inhibitors and novel degraders to advanced genetic engineering strategies, all designed to dismantle key metabolic barriers in the TME and generate resilient, persistent CAR-T cells for solid tumors.

Our Service Process

Required Starting Materials:

• Target Antigen Sequence.
• Tumor Cell Lines or Biopsy Samples.
• T cell Source Material.

Key Steps:

Final Deliverables:

• Custom CAR Vector Construct with integrated TME modulation elements.
• Comprehensive Efficacy Report (including tumor burden, T cell persistence, and exhaustion marker analysis).

Key Advantages

• Customized Dual-Blockade Strategy: Development of bespoke CAR-T cells with integrated resistance mechanisms against both the IDO1 and ARG1 metabolic checkpoints, specifically tailored to the immunosuppressive profile of your target tumor.
• Integrated TME Profiling: Documentation and procedures for initial metabolic assessment of the tumor microenvironment are rigorously assessed, ensuring the inhibitory strategy is maximally effective.
• Enhanced T Cell Persistence Optimization: We optimize culture conditions and cell bank procedures to maximize CAR-T viability, cytokine production, and cytotoxic yield, ensuring peak performance upon adoptive transfer.

FAQs

Why Choose Us?

We provide a unique dual metabolic checkpoint blockade strategy, simultaneously targeting the IDO1/kynurenine and ARG1/L-arginine pathways to fundamentally overcome key immunosuppressive mechanisms in the tumor microenvironment. Our approach enables the development of CAR-T cells with superior infiltration, persistence, and antitumor efficacy against solid tumors.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T service in our research has significantly improved the sustained cytotoxic function of our lead CAR-T candidate. We observed a clear mitigation of Kynurenine-induced apoptosis, a major benefit not seen with our previous 4-1BB co-stim design alone." M. K***in.

"The dual IDO1/ARG1 blockade strategy facilitated by Creative Biolabs was essential. Our challenge was MDSC accumulation in the solid tumor core, which depleted L-Arginine. Their Arg1-targeting approach effectively cleared this suppressive population, which we confirmed using Published Data benchmarks." P. J***son.

"Creative Biolabs' comprehensive workflow, from TME profiling to in vivo validation under lymphodepleting conditions, streamlined our preclinical phase by nearly two months. The clear data on T-cell persistence in the xenografts gave us the confidence needed to move directly into clinical trials." S. L***er.

How to contact us?

Ready to realize the full potential of your CAR-T pipeline for solid tumors? Our expert team is ready to conduct an in-depth analysis of your existing data and leverage these insights to develop a bespoke metabolic reprogramming strategy, designed to overcome current therapeutic challenges.

Contact our team to learn more and explore a potential collaboration.

Reference

1. Meireson, Annabel et al. "IDO Expression in Cancer: Different Compartment, Different Functionality?" Frontiers in immunology vol. 11 531491. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2020.531491.